TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04151589

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ANGEL Intervention Package and Toolbox
Description: The interventional measures include emergency work flow management app on smartphone, specialized training, assessment of quality improvement outcomes and feedback on a regular basis, patient-centred management frame based lean six-sigma, and other specialised approach.
Study: NCT06530004

Intervention type: DRUG
Intervention: Rituximab
Description: B lymphocyte reconstitution was performed regularly after the administration of rituximab, and 1-4 doses of rituximab were given according to the exhaustion of B cells in children.

Intervention type: DRUG
Intervention: Rituximab
Description: B lymphocyte reconstitution was performed regularly after the administration of rituximab, and 1-4 doses of rituximab were given according to the exhaustion of B cells in children.
Study: NCT02930395

Intervention type: PROCEDURE
Intervention: serum S100B assay
Study: NCT00317018

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Evidence-Based Quality Improvement
Description: The implementation intervention is known as Evidence-Based Quality Improvement (EBQI). EBQI is an adaptation of the Plan-Do-Study-Act cycles of Continuous Quality Improvement that emphasizes empirical evidence and the involvement of clinical and implementation experts (i.e., researchers). In the EBQI implementation intervention, both researchers (clinical and implementation experts) and local staff participate fully in the quality improvement process, with the researchers facilitating rather than dictating implementation efforts. Using EBQI methods, researchers and local staff adapt evidence-based practices for local resources, needs and preferences while maintaining fidelity to the evidence-base. PDSA cycles are used to continuously revise the adapted evidence-based practice based on feedback during pilot tests.
Study: NCT02775370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Apatinib Mesylate will be administered orally at 500 mg once daily for 5 consecutive days, and this was followed by a 2-day rest every week; each cycle consisted of 28 days
Study: NCT03405090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Citrate
Description: 100 mcg fentanyl citrate will be inhaled via nebulizer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combivent
Description: 0.5 mg ipratropium bromide + 2.5 mg salbutamol will be inhaled via nebulizer
Study: NCT03176264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: 400 mg every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 5 mg/kg every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: Combination of chemotherapy administered every 2 weeks: oxaliplatin (85mg/m2), 5-Fluorouracil (2400mg/m2) and folinic acid (=leucovorin, 400mg/m2)
Study: NCT00230750

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A/H5N1 Vaccine
Description: Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit-dose vials containing 90-mcg/mL. Dosages: 45 mcg or 90 mcg administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A/H5N1 Vaccine
Description: Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit-dose vials containing 90-mcg/mL. Dosages: 45 mcg or 90 mcg administered intramuscularly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline placebo.
Study: NCT02679326

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Therapeutic ultrasound

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound
Study: NCT03156881

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global Osteopathic Treatment
Description: The study objectives is to observe a difference and improvement of liver function based on liver enzyme count from blood work after osteopathic treatments. Also to observe an improvement in the patients quality of life after receiving treatment and in their readiness to change.~Osteopathy is a type of manual therapy that uses gentle manipulations taking into consideration of the whole person when treating. For example if the liver is being treated, osteopaths look for mobility, to carry out its proper function. However one will also assess its interrelationships that can influence the liver such as its neighbours, articulating structures, example the diaphragm as well as its neurological input from T5-T9 for instance.
Study: NCT01644864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.375% ROPIVACAINE

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03112109

Intervention type: OTHER
Intervention: 'New care'
Description: Frail elderly receiving care within new organisational models delivering integrated healthcare (IHC) supported by ICT infrastructure (electronically shared-care platform) as provided by pilot sites individually.
Study: NCT01955187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACROLIMUS
Description: Initial dose: 0.05 mg/Kg/day, adjusted to achieve blood trough levels of 5-7 ng/ml) for six months. Starting at the end of month 6, tacrolimus dosage will be reduced by 25% per month, resulting in a complete withdrawal at the end of month 9.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RITUXIMAB
Description: A dose 1 g IV will be given during month 6 (at day 180), before the onset of tacrolimus dose reduction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: METHYLPREDNISOLONE
Description: Month 1: 1g IV methylprednisolone daily for three doses (days 1, 2, and 3), Oral methylprednisolone (0.5mg/kg/day) for 27 days (days 4 to 30). Months 3, and 5: Repeat Month 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CYCLOPHOSPHAMIDE
Description: Month 2: Oral Cyclophosphamide (2.0 mg/kg/day) for 30 days. Months 4, and 6: Repeat month 2.
Study: NCT03251729

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical cerclage
Description: Transvaginal cervical cerclage placed between 18 0/7 - 23 6/7 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Description: Vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Vaginal progesterone
Description: Vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks
Study: NCT02963090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Topotecan at 1.25mg/m2 on days 1 to 5 every 21-days until progression of disease or unacceptable toxicities.~Patients with progression of disease by RECIST 1.1 will be allowed cross over to receive pembrolizumab 200 mg IV every 21-days for up to 1 year until progression of disease or unacceptable toxicities.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV every 21-days until progression of disease or unacceptable toxicities.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: 200 mg IV every 21-days until progression of disease or unacceptable toxicities.
Study: NCT01863147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin and acarbose
Description: Sitagliptin group: The intervention drug is sitagliptin. Acarbose group: The intervention drug is acarbose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin and acarbose
Description: Sitagliptin group: The intervention drug is sitagliptin. Acarbose group: The intervention drug is acarbose.
Study: NCT04038918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: progressive muscle relaxation exercise
Description: In addition to standard postoperative rehabilitation, intervention group will receive PMR exercises focusing on reduce overall body tension, anxiety. The intervention group will perform the PMR exercise in accompanying with a qualified physiotherapist for postoperative 3 days (2 times/day; along 30 minutes for one session).

Intervention type: OTHER
Group type: OTHER
Intervention: standard postoperative physiotherapy program
Description: After surgery, patients will receive standard postoperative rehabilitation program including active-assistive and active range of motion exercises, isometric and isotonic strengthening exercises, gait training and transfer training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard postoperative physiotherapy program
Description: After surgery, patients will receive standard postoperative rehabilitation program including active-assistive and active range of motion exercises, isometric and isotonic strengthening exercises, gait training and transfer training.
Study: NCT04340661

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BIOintestil
Description: Ginger ryzoma powder and Palmrose essential oil (Cymbopogon Martinii)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Cornstarch
Study: NCT00767390

Intervention type: DEVICE
Intervention: ACL Patch
Description: Observe and characterize the changes in relative conductivity between the six ACL patches over period of six hours. Investigation only involves passive data collection on pressure impact and adhesiveness properties of ACL patches.
Study: NCT03025750

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPV-Al SSI
Description: Total of three primary injections of IPV-Al SSI, one at 2, 4 and 6 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV SSI
Description: Total of three primary injections of IPV SSI, one at 2, 4 and 6 months of age
Study: NCT00429780

Intervention type: BIOLOGICAL
Group type: NO_INTERVENTION
Intervention: Alum-ALM + BCG
Description: Alum-ALM + BCG 200 ug per injection
Study: NCT02845232

Intervention type: OTHER
Intervention: Transfusion
Description: The number and type of blood products administered were registered from the time of diagnosis to the time of death corresponding for all patients to the time of last follow-up. Transfusion of a single unit of packed red blood cell (PRBC) or one whole blood-derived platelet concentrate (PC) or fresh frozen plasma (FFP) was considered a transfusion event and considered for statistical analysis.

Intervention type: OTHER
Intervention: Transfusion
Description: The number and type of blood products administered were registered from the time of diagnosis to the time of death corresponding for all patients to the time of last follow-up. Transfusion of a single unit of packed red blood cell (PRBC) or one whole blood-derived platelet concentrate (PC) or fresh frozen plasma (FFP) was considered a transfusion event and considered for statistical analysis.

Intervention type: OTHER
Intervention: Transfusion
Description: The number and type of blood products administered were registered from the time of diagnosis to the time of death corresponding for all patients to the time of last follow-up. Transfusion of a single unit of packed red blood cell (PRBC) or one whole blood-derived platelet concentrate (PC) or fresh frozen plasma (FFP) was considered a transfusion event and considered for statistical analysis.
Study: NCT02617953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS(A)
Description: repetitive transcranial magnetic stimulation:1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex , each consisting of 4 days of rTMS treatment.~auditory ERP,continuous resting EEG and MRI are measured pre-treatment rTMS and auditory ERP,continuous resting EEG are measured two weeks after rTMS treatment. Tinnitus subjects were asked to perform an interval duration paried pulse task before and after the rTMS train.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS(B)
Description: repetitive transcranial magnetic stimulation:1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex , each consisting of 4 days of rTMS treatment.~auditory ERP,continuous resting EEG and MRI are measured pre-treatment rTMS and auditory ERP,continuous resting EEG are measured two weeks after rTMS treatment. Tinnitus subjects were asked to perform an interval duration paried pulse task before and after the rTMS train.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham condition(C)
Description: The sham stimulation looks and sounds like the active coil, but diverts the magnetic field away from the patient.~auditory ERP,continuous resting EEG and MRI are measured pre-treatment rTMS and auditory ERP,continuous resting EEG are measured two weeks after rTMS treatment. Tinnitus subjects were asked to perform an interval duration paried pulse task before and after the rTMS train.
Study: NCT03240822

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Penile Transplant
Description: Penile Allotransplantation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monoclonal Antibody (Humanized Anti-CD52)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Study: NCT00297947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine
Description: Participant will receive 1200 mg/day of quetiapine in twice daily dosing for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine
Description: Participant will receive 600 mg/day of quetiapine for 8 weeks.
Study: NCT03909490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preference elicitation tool
Description: Ranking tool to assess patient preferences for trigger finger treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: handout
Description: handout with information about trigger fingers
Study: NCT01052610

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sublingual house dust mites allergen extract
Description: Staloral 300 IR, Stallergenes, France

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo in sublingual applicator
Description: placebo for Staloral 300 IR, Stallergenes, France
Study: NCT01706705

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracavitary Applicator Placement
Description: MRI-compatible applicator inserted using ultrasound guidance to verify tandem placement in the uterus. Tandem and ovoids, tandem and cylinders, or tandem and ring chosen to accommodate patient's tumor and vaginal anatomy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Description: CT scan performed after implant is placed in operating room. CT scan should take about 20 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI scan performed after implant is placed in the operating room. MRI should take about 45 minutes.
Study: NCT00052078

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Participants received CBT.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Participants received CBT.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants were treated with a placebo pill.
Study: NCT02209090

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: maternal modified sims position
Description: Maternal Modified Sims position during at least 40 minutes for each 60 minutes

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: maternal free positions
Description: At least 40 minutes each hour during labour
Study: NCT03414177

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Asthma Subspecialty Follow-up Visits
Description: Pediatric patients with persistent asthma will be recruited to compare outcomes among patients with follow-up visits managed via telemedicine vs. in-person visits.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Asthma Subspecialty Follow-up Visits
Description: Pediatric patients with persistent asthma will be recruited to compare outcomes among patients with follow-up visits managed via telemedicine vs. in-person visits.
Study: NCT03714659

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lipogems
Description: Lipogems is a closed-loop system designed to break up adipose tissue into micro-fragmented adipose tissue without additives; therefore, meeting FDA requirements for minimal manipulation. A small volume of adipose tissue is harvested from the abdomen, thigh, or other location. The lipoaspirate is fed into the device through a reduction filter, and is then cleansed of blood and oil residues using a sterile saline solution. This fat-saline solution is then shaken for 30 seconds in a device containing stainless steel ball bearings, which further fragments and washes the lipoaspirate. Once the tissue is purified and fragmented, it is collected in 10cc sterile syringes and subsequently injected into the meniscus and knee joint.
Study: NCT02658877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab will be dosed according to dosing and U.S. administration guidelines for omalizumab. Omalizumab will be dosed every 2-4 weeks based on the patient's pre treatment serum IgE level (IU/mL) and initial visit body weight (kg). Omalizumab will be delivered as a subcutaneous injection. Standard safety precautions for dosing will be observed, including clinical observation after dosing, and provision of an epinephrine pen. Maintenance asthma treatment will remain unchanged.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline with a volume of injection frequency indicated based on the patient's serum IgE and body weight, delivered subcutaneously and supplied by Novartis Pharma.
Study: NCT01290276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ond-PR1
Description: Single oral dose of 8 mg of ondansetron pulsatile-release formulation 1 (Ond-PR1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ond-PR1
Description: Single oral dose of 8 mg of ondansetron pulsatile-release formulation 1 (Ond-PR1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ond-PR1 + MPh-IR
Description: Single oral dose of 8 mg of ondansetron pulsatile-release formulation 1 (Ond-PR1) plus 10 mg methylphenidate immediate release (Mph-IR)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ond-PR1 + MPh-IR
Description: Single oral dose of 8 mg of ondansetron pulsatile-release formulation 1 (Ond-PR1) plus 10 mg methylphenidate immediate release (Mph-IR)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ond-PR2
Description: Single oral dose of 8 mg ondansetron pulsatile-release formulation 2 (Ond-PR2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ond-PR2
Description: Single oral dose of 8 mg ondansetron pulsatile-release formulation 2 (Ond-PR2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ond-PR2 +_ MPh-IR
Description: Single oral dose of 8 mg of ondansetron pulsatile-release formulation 2 (Ond-PR2) plus 10 mg methylphenidate immediate release (Mph-IR)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ond-PR2 +_ MPh-IR
Description: Single oral dose of 8 mg of ondansetron pulsatile-release formulation 2 (Ond-PR2) plus 10 mg methylphenidate immediate release (Mph-IR)
Study: NCT02480192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBT for Menopausal Symptoms (CBT-Meno)
Description: This 12-week CBT-based group treatment program consists of a combination of components including: a) psychoeducation about the nature of menopause including examination about thoughts and beliefs, b) cognitive and behavioural modification related to vasomotor symptoms, c) cognitive-behavioural strategies for depression, e) cognitive-behavioural strategies for anxiety and panic, d) sleep hygiene and cognitive-behavioural strategies for sleep difficulties, f) psychoeducation and lifestyle and behavioural modifications for urogenital complaints, and g) psychoeducation and cognitive-behavioural strategies for sexual concerns.
Study: NCT01815086

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)
Description: Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)
Study: NCT01250925

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ReNu MultiPlus® MultiPurpose Solution
Description: Contact lens care regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPTI-FREE® RepleniSH®
Description: Contact Lens care regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clear Care®
Description: Contact lens care regimen
Study: NCT00959686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine at the dose of 120 mg/m2 IV over 60 minutes on days 1 and 2 every 21 days for 6 cycles
Study: NCT00678301

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Synflorix™
Description: 3 IM doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Polio Sabin™
Description: 3 oral doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Polio Sabin™
Description: 3 oral doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Zilbrix™ Hib
Description: 3 IM doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Zilbrix™ Hib
Description: 3 IM doses.
Study: NCT00426127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin